approval of Eliquis (apixaban) to prevent stroke in A fib will intensify the marketing war among the NEW oral anticoagulants

The approval of Eliquis (apixaban) to prevent stroke in A fib will intensify the marketing war among the NEW oral anticoagulants.

Eliquis will join Pradaxa (dabigatran) and Xarelto (rivaroxaban) as alternatives to warfarin for atrial fibrillation.

Keep in mind how the new oral anticoagulants stack up for A fib.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote